Works matching IS 01676997 AND DT 2014 AND VI 32 AND IP 5
Results: 29
A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3)
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 995, doi. 10.1007/s10637-014-0101-x
- By:
- Publication type:
- Article
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 795, doi. 10.1007/s10637-014-0102-9
- By:
- Publication type:
- Article
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 1017, doi. 10.1007/s10637-014-0111-8
- By:
- Publication type:
- Article
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 946, doi. 10.1007/s10637-014-0112-7
- By:
- Publication type:
- Article
Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 913, doi. 10.1007/s10637-014-0103-8
- By:
- Publication type:
- Article
The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 815, doi. 10.1007/s10637-014-0107-4
- By:
- Publication type:
- Article
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 928, doi. 10.1007/s10637-014-0109-2
- By:
- Publication type:
- Article
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 937, doi. 10.1007/s10637-014-0110-9
- By:
- Publication type:
- Article
In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 806, doi. 10.1007/s10637-014-0105-6
- By:
- Publication type:
- Article
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 1005, doi. 10.1007/s10637-014-0106-5
- By:
- Publication type:
- Article
Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 1036, doi. 10.1007/s10637-014-0113-6
- By:
- Publication type:
- Article
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 955, doi. 10.1007/s10637-014-0114-5
- By:
- Publication type:
- Article
A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 969, doi. 10.1007/s10637-014-0115-4
- By:
- Publication type:
- Article
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 976, doi. 10.1007/s10637-014-0116-3
- By:
- Publication type:
- Article
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 985, doi. 10.1007/s10637-014-0118-1
- By:
- Publication type:
- Article
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 825, doi. 10.1007/s10637-014-0120-7
- By:
- Publication type:
- Article
Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 838, doi. 10.1007/s10637-014-0126-1
- By:
- Publication type:
- Article
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 851, doi. 10.1007/s10637-014-0129-y
- By:
- Publication type:
- Article
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 860, doi. 10.1007/s10637-014-0130-5
- By:
- Publication type:
- Article
Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 871, doi. 10.1007/s10637-014-0131-4
- By:
- Publication type:
- Article
Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 883, doi. 10.1007/s10637-014-0132-3
- By:
- Publication type:
- Article
The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report.
- Published in:
- 2014
- By:
- Publication type:
- Report
Resistance mechanisms of cancer cells to the novel vacuolar H-ATPase inhibitor archazolid B.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 893, doi. 10.1007/s10637-014-0134-1
- By:
- Publication type:
- Article
Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 1048, doi. 10.1007/s10637-014-0063-z
- By:
- Publication type:
- Article
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 783, doi. 10.1007/s10637-014-0090-9
- By:
- Publication type:
- Article
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 904, doi. 10.1007/s10637-014-0099-0
- By:
- Publication type:
- Article
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 1028, doi. 10.1007/s10637-014-0100-y
- By:
- Publication type:
- Article